NCT00939289已完成不适用
Pilot Study of Concurrent Use of the SEVEN® and FreeStyle Navigator® Continuous Glucose Monitoring Systems in Adults With Type 1 Diabetes Mellitus
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- DexCom, Inc.
- 入组人数
- 14
- 试验地点
- 1
- 主要终点
- CGM System(s) performance (relative to YSI and/or SMBG) evaluated by standard accuracy metrics
研究概览
简要总结
The purpose of this pilot study is to evaluate performance of the SEVEN System and the Navigator System when both devices are worn concurrently by subjects with type 1 diabetes mellitus.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18 years or older;
- •Have been diagnosed with type 1 diabetes and are on multiple daily injections (MDI) or Continuous Subcutaneous Insulin Infusion (CSII) insulin therapy;
- •Willing not to inject insulin or wear an insulin pump infusion set within 3 inches from either Sensor site;
- •Willing to participate in an 8-hour in-clinic session on study Days 5, 10, and 15 and be willing to take 4 fingersticks per hour and have 4 blood draws per hour for the 8-hour duration of each of these in-clinic sessions;
- •Willing to take a minimum of 6 fingersticks per day during home use;
- •Willing to refrain from the use of acetaminophen during this study and for at least 24-hours prior to enrollment;
- •Willing not to schedule an magnetic resonance (MRI) scan, computed tomography (CT) scan, x-ray, for the duration of the study;
- •Able to speak, read, and write English.
排除标准
- •Have extensive skin changes/diseases that preclude wearing the Sensor on normal skin (e.g., extensive psoriasis, recent burns or severe sunburn, extensive eczema, extensive scarring, extensive tattoos, dermatitis herpetiformis) at the proposed wear sites;
- •Subjects who have a known allergy to medical-grade adhesives;
- •Are pregnant as demonstrated by a positive pregnancy test within 72 hours of insertion;
- •Have a hematocrit that is less than 30%, or greater than 55%;
- •Current participation in another investigational study protocol (if a subject has recently completed participation in another drug study, the subject must have completed that study at least 30 days prior to being enrolled in this study);
- •Have any condition that, in the opinion of the Investigator, would interfere with their participation in the trial or pose an excessive risk to study staff handling venous blood samples (e.g., known history of hepatitis B or C).
结局指标
主要结局
CGM System(s) performance (relative to YSI and/or SMBG) evaluated by standard accuracy metrics
时间窗: 15 days
次要结局
- Documentation of all reported Adverse Device Effects, Serious Adverse Device Events, and Unanticipated Adverse Device Effects(15 days)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
Bimanual Robotic Exoskeletal Platform for the Treatment of the Upper Limb in Patients With Stroke. A Feasibility StudyStrokeNCT05176600Wearable Robotics srl.20
已完成
1 期
A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid TumorsMelanomaCarcinoma, HepatocellularColorectal NeoplasmsNCT05091346Eisai Inc.89
已完成
不适用
Tolerance and Efficacy of a Predigested, High Protein, High Omega 3 Fat Enteral Feeding Formula Versus a Standard Formula In Multiple Intensive Care Unit SettingsCritical IllnessEnteral FeedingNCT01448135Columbia University50
已完成
早期 1 期
Fludeoxyglucose F 18 PET/CT Imaging in Finding Cancer in Patients Undergoing Surgery for Solid TumorsUnspecified Adult Solid Tumor, Protocol SpecificNCT00816335Ohio State University Comprehensive Cancer Center65
已完成
4 期
Testing Integrative Smoking Cessation for HIV PatientsSmokingSmoking CessationHIV InfectionsNCT05030766University of Miami95